"Cabozantinib has a long half-life of 55 hours."@en . "Cabozantinib is eliminated mostly by the feces (54%) and also by the urine (27%)."@en . "Cabozantinib L-malate"@en . . . "849217-68-1"@en . "Cabozantinib (S)-malate"@en . "Cometriq"@en . "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2."@en . "Cabozantinib has extensive plasma protein binding (\u2265 99.7%)."@en . "For the treatment of metastatic medullary thyroid cancer. "@en . "After oral administration, peak plasma concentration was achieved in 2-5 hours."@en . "BMS 907351"@en . "# Durante C, Russo D, Verrienti A, Filetti S: XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21314233"@en . . . "Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as COMETRIQ\u2122, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. "@en . "XL-184"@en . "BMS907351"@en . "XL184"@en . . . "At steady state, the clearance is 4.4 L/hr."@en . "Cabozantinib has a black box warning of serious gastrointestinal fistulas and perforations, and potentially fatal hemoptysis and gastrointestinal hemorrhage."@en . . "approved"@en . . . . "cabozantinib s-malate"@en . "Avoid grapefruit juice. Combination may increase levels of cabozantinib. Also avoid all other strong CYP3A4 inhibitors."@en . "Cabozantinib"@en . "The volume of distribution is 349L. "@en . . . "XL 184"@en . "Humans and other mammals"@en .